AU2001227847A1 - Antisense modulation of pepck-cytosolic expression - Google Patents
Antisense modulation of pepck-cytosolic expressionInfo
- Publication number
- AU2001227847A1 AU2001227847A1 AU2001227847A AU2784701A AU2001227847A1 AU 2001227847 A1 AU2001227847 A1 AU 2001227847A1 AU 2001227847 A AU2001227847 A AU 2001227847A AU 2784701 A AU2784701 A AU 2784701A AU 2001227847 A1 AU2001227847 A1 AU 2001227847A1
- Authority
- AU
- Australia
- Prior art keywords
- pepck
- antisense modulation
- cytosolic expression
- cytosolic
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01032—Phosphoenolpyruvate carboxykinase (GTP) (4.1.1.32)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2561/00—Nucleic acid detection characterised by assay method
- C12Q2561/113—Real time assay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/488,671 US6187545B1 (en) | 2000-01-19 | 2000-01-19 | Antisense modulation of pepck-cytosolic expression |
| US09488671 | 2000-01-19 | ||
| PCT/US2001/000953 WO2001053540A1 (en) | 2000-01-19 | 2001-01-11 | Antisense modulation of pepck-cytosolic expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001227847A1 true AU2001227847A1 (en) | 2001-07-31 |
Family
ID=23940648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001227847A Abandoned AU2001227847A1 (en) | 2000-01-19 | 2001-01-11 | Antisense modulation of pepck-cytosolic expression |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6187545B1 (en) |
| EP (1) | EP1254259A1 (en) |
| JP (1) | JP2003520051A (en) |
| AU (1) | AU2001227847A1 (en) |
| WO (1) | WO2001053540A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092647A1 (en) * | 2001-08-08 | 2003-05-15 | Crooke Rosanne M. | Antisense modulation of cholesteryl ester transfer protein expression |
| US20030054354A1 (en) * | 2001-08-23 | 2003-03-20 | Bennett C. Frank | Use of antisense oligonucleotide libraries for identifying gene function |
| US20040038223A1 (en) * | 2001-10-02 | 2004-02-26 | Glennda Smithson | Novel proteins and nucleic acids encoding same |
| US20030224512A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
| EP1537239A4 (en) * | 2002-08-06 | 2007-02-07 | Curagen Corp | Methods of identifying compounds that modulate protein activity |
| ES2420914T3 (en) * | 2002-11-13 | 2013-08-27 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| DE10361502A1 (en) * | 2003-12-23 | 2005-07-28 | Phenion Gmbh & Co. Kg | Cosmetic or pharmaceutical preparations containing superstructure-forming nucleic acid sequences |
| US20050164271A1 (en) * | 2004-01-20 | 2005-07-28 | Sanjay Bhanot | Modulation of glucocorticoid receptor expression |
| CA2612639C (en) * | 2005-06-24 | 2014-08-26 | Samvel Avakovich Kazaryan | Current collector for double electric layer electrochemical capacitors and method of manufacture thereof |
| AU2013262649A1 (en) * | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating smn gene family expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| EP2850190B1 (en) | 2012-05-16 | 2020-07-08 | Translate Bio MA, Inc. | Compositions and methods for modulating mecp2 expression |
| US10174328B2 (en) | 2013-10-04 | 2019-01-08 | Translate Bio Ma, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| EP3976010A4 (en) * | 2019-06-03 | 2023-08-02 | Quralis Corporation | Oligonucleotides and methods of use for treating neurological diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580722A (en) * | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
| US5789573A (en) * | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
-
2000
- 2000-01-19 US US09/488,671 patent/US6187545B1/en not_active Expired - Lifetime
-
2001
- 2001-01-11 WO PCT/US2001/000953 patent/WO2001053540A1/en not_active Ceased
- 2001-01-11 AU AU2001227847A patent/AU2001227847A1/en not_active Abandoned
- 2001-01-11 EP EP01901998A patent/EP1254259A1/en not_active Withdrawn
- 2001-01-11 JP JP2001553399A patent/JP2003520051A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003520051A (en) | 2003-07-02 |
| EP1254259A1 (en) | 2002-11-06 |
| US6187545B1 (en) | 2001-02-13 |
| WO2001053540A1 (en) | 2001-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
| AU2212600A (en) | Antisense modulation of g-alpha-i1 expression | |
| AU6296099A (en) | Antisense modulation of g-alpha-12 expression | |
| AU2001277054A1 (en) | Antisense modulation of lysophospholipase i expression | |
| AU2001229493A1 (en) | Antisense modulation of mekk2 expression | |
| AU2002227435A1 (en) | Antisense modulation of calreticulin expression | |
| AU2002309819A1 (en) | Antisense modulation of PTP1B expression | |
| AU2001289046A1 (en) | Antisense modulation of her-2 expression | |
| AU2001229447A1 (en) | Antisense modulation of smad7 expression | |
| AU2001278077A1 (en) | Antisense modulation of ptp1b expression | |
| AU2001261808A1 (en) | Antisense modulation of pten expression | |
| AU2001263171A1 (en) | Antisense modulation of tert expression | |
| AU2001239971A1 (en) | Antisense modulation of parp expression | |
| AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
| AU6115400A (en) | Antisense modulation of mekk5 expression | |
| AU2002366788A1 (en) | Antisense modulation of ship-1 expression | |
| AU2002318139A1 (en) | Antisense modulation of src-c expression | |
| AU2001288968A1 (en) | Antisense modulation of btak expression | |
| AU2209000A (en) | Antisense modulation of pepck-mitochondrial expression | |
| AU2002226064A1 (en) | Antisense modulation of talin expression | |
| AU2002230869A1 (en) | Antisense modulation of hepsin expression | |
| AU2002357102A1 (en) | Antisense modulation of cd36l1 expression | |
| AU5486700A (en) | Antisense modulation of g-alpha-s1 expression | |
| AU2001287136A1 (en) | Antisense modulation of glioma-associated oncogene-1 expression | |
| AU2410600A (en) | Antisense modulation of g-alpha-i3 expression |